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            Mechanisms of innate and adaptive immunity play a pivotal role in the 
development of cancer. Chronic infl  ammation can drive tumor development, 
but antitumor immunity can also restrict or even prevent tumor growth. 
New data show that feed-forward signals downstream of the receptor for 
advanced glycation end-products (RAGE) can fuel chronic infl  ammation, 
creating a microenvironment that is ideal for tumor formation. 
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  Chronic infl  ammation is a major 
causative factor in a wide range of hu-
man and murine malignancies. In hu-
mans, infl  ammation associated with the 
hepatitis B and C viruses is the primary 
cause of liver cancer, and the bacterium 
  Helicobacter pylori   plays a central role in 
the development of most cancers of 
the stomach (  1, 2  ). Beyond infections, 
many autoimmune diseases are associ-
ated with an increased risk of lymphoma, 
and the inappropriate immune response 
to commensal fl  ora in ulcerative colitis 
is strongly linked to colon cancer (  3, 4  ). 
  Evidence now links infl  ammation to 
tumor development in both genetic tu-
mor syndromes and in the context of 
chronic carcinogen exposure. Adminis-
tration of nonsteroidal antiinfl  ammatory 
drugs (NSAIDs) reduces the incidence 
of colon cancer in patients with familial 
adenomatous polyposis (FAP) (  5  ) and, 
perhaps more remarkably, reduces the 
incidence of lung cancer in smokers, the 
principal cause of cancer-related death 
worldwide (  6  ). 
  Studies performed in a variety of 
mouse models of cancer have paralleled 
the fi  ndings from human tumors, but the 
precise role of infl   ammation in tumor 
development remains incompletely un-
derstood. Several key mediators have 
been identifi  ed that link chronic infl  am-
mation to tumor development, yet in 
many cases, the pathways critical for the 
initiation and maintenance of chronic 
  infl  ammation are unknown. On   p. 275   
in this issue, Gebhardt et al. [  7  ] present 
evidence that signals downstream of 
RAGE are critical for the development 
of tumor-promoting infl  ammation in a 
mouse model of skin cancer. 
  Tumor-promoting cytokines 
  Production of acute infl  ammatory cyto-
kines by cells of the innate immune sys-
tem, including macrophages and mast 
cells, plays an essential role in infl  amma-
tion-driven tumor development. Cyto-
kines such as TNF, interleukin (IL)-6, 
and IL-1     have myriad eff  ects in the tu-
mor microenvironment, promoting cell 
growth and survival as well as angio-
genesis and the recruitment of immune 
eff  ector cells (  2  ). 
  Which cytokines are required for tu-
mor development depends largely on the 
model being examined. TNF plays an es-
sential role in several models of cancer, 
and is a critical infl  ammatory mediator in 
many autoimmune diseases of both mice 
and humans, primarily acting via induc-
tion of NF-    B (  2  ). IL-6 acts both as a 
mitogen and an angiogenic factor and has 
been implicated in many of the same pro-
cesses as TNF. IL-6 plays an important 
role in carcinogen-driven liver cancer, 
and has recently been identifi  ed as an im-
portant driving factor in non  –  smoking-
related lung cancer in humans (  8  –  10  ). 
IL-1 can activate NF-   B in a manner sim-
ilar to TNF, and polymorphisms in IL-1 
have been linked to gastric cancer (  11  ). 
  Inciting infl  ammation 
  Not surprisingly, tumor-promoting in-
fl  ammation can be induced by the same 
pathways that respond to microbial in-
fections, suggesting that tumors may be 
aberrant consequences of initially physi-
ological immune responses.   
  Recent work has positioned myeloid 
diff  erentiation factor 88 (MyD88), which 
is a critical downstream signaling mole-
cule for both the Toll-like receptor 
(TLR) family of microbial pattern recog-
nition receptors and the IL-1 and -18 re-
ceptors (IL-1R and -18R), as a central 
player in infl  ammation-driven  tumori-
genesis. In the diethylnitrosamine model 
of liver cancer, MyD88-dependent in-
duction of IL-6 is critical for tumor 
formation (  12  ). MyD88-defi  cient mice 
treated with the topical carcinogen 7,12-
dimethylbenz[a]anthracene (DMBA), 
followed by treatment with the proin-
fl  ammatory phorbol-ester TPA, devel-
oped fewer epithelial tumors than did 
wild-type mice (  13  ). Surprisingly, 3-
methyl    cholanthrene (MCA)  –  induced 
sar  comas were also reduced in MyD88-
defi  cient mice, despite the lack of an 
obvious role for infl  am    mation in this 
model (  13  ). 
  MyD88-dependent signaling is also 
required in some genetic tumor models. 
In the APC 
min/+   model of human FAP, 
MyD88 defi  ciency was associated with 
decreased infl  ammatory  cytokine  pro-
duction within the tumor microenvi-
ronment (  14  ). This reduction correlated 
with a decrease in both the number and 
size of spontaneously arising polyps. 
  Although these fi  ndings bring us one 
step closer to understanding the nature 
of the signals driving tumor-promoting 
infl  ammation, the factors responsible for 
engaging MyD88-dependent pathways 
are still obscure. TLRs can recognize a 
wide range of highly conserved micro-
bial products, potentially implicating 
occult infections or normal fl  ora in tu-
mor-associated infl  ammation. 
  MyD88 may also facilitate so-called 
  “  sterile  ”   infl   ammation, either through 
TLR-dependent recognition of en do  ge-
nous adjuvants or through IL-1R sig-
naling. IL-1R signaling is important for 
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model induces S100a8 and S100a9 syn-
thesis in epithelial cells, likely leading to 
a feed-forward loop that further aggra-
vates the infl  ammatory environment. Reg  -
ulatory circuits limiting RAGE-mediated 
infl  ammation undou  btedly exist, but these 
as yet uncharacterized pathways are clearly 
not suffi   cient to prevent tumor onset 
in the time frame of these experiments. 
Interestingly, the requirement for RAGE 
can be bypassed by more frequent appli-
cation of TPA, suggesting that other, 
more rapidly self-limiting infl  ammatory 
pathways can substitute for RAGE if the 
infl  ammation-inciting agent is allowed 
to persist. 
  Protective immunity 
  In contrast to the tumor-promoting 
eff  ects of chronic infl  ammation, increas-
ing evidence suggests that adaptive im  -
munity is responsible for recognizing 
and rejecting malignant cells (for review 
see reference   21  ). The protective eff  ect 
of adaptive immunity is most obvious 
in the case of tumors with viral etiolo-
gies, but immunodefi   ciencies in both 
mice and humans have also been asso-
ciated with an increased incidence of 
many tumors without a clear viral eti-
ology (  21  ). Consistent with a role for 
adaptive immunity in regulating tumor 
growth, spontaneous lymphocytic infi  l-
trates can be observed in a variety of 
diff  erent human cancers and, in some, 
these infi  ltrates correlate with a favor-
able prognosis (  21  –  22  ). Once a tumor 
is established, immunosuppression is a 
common feature of the microenviron-
ment, with most tumors infi  ltrated by 
immunosuppressive myeloid and lym-
phoid cells (  21  ). The expression of anti-
infl  ammatory factors is also common in 
tumors, suggesting that overcoming an 
antitumor immune response is an im-
portant step in tumorigenesis. 
  The mechanism by which adaptive 
immune cells can control tumor growth 
has been studied extensively using the 
MCA tumor model. In this system, IFN-
      –  producing T cells play an essential role 
in impeding tumor development. Mice 
with defects in T cell immunity exhibit an 
increased incidence of tumor formation 
after MCA application, and the tumors 
that arise in these mice are more easily 
mechanisms is thus an essential feature of 
tumor-promoting infl  ammation. 
  Although in many cases, such as in-
fection or autoimmunity, the mechanisms 
that prevent the resolution of infl  amma-
tion are still unclear, genetic defects in key 
regulatory proteins can enhance tumor 
formation. Loss of TIR8, which is a neg-
ative regulator of IL-1R/TLR signaling, 
exacerbates infl  ammation in the dextran 
sulfate sodium model of colitis, leading to 
a substantially increased risk of colon can-
cer (  18  –  19  ). Similarly, loss of IL-1 recep-
tor antagonist, a secreted protein that 
blocks IL-1 function, accelerates tumor 
onset and increases tumor aggressiveness 
in the DMBA/TPA model (  16  ). 
  The loss of immune regulation may 
also aggravate disease in APC 
min/+   mice. 
Infusion of regulatory T (T reg) cell  –
  depleted T cells into APC 
min/+   mice in-
creases polyp formation and leads to the 
development of spontaneous mammary 
tumors (  20  ). 
  One of the more intriguing elements 
of RAGE-dependent infl  ammation is the 
ability of RAGE to up-regulate its own 
ligands. Gebhart et al. (  7  ) demonstrate that 
RAGE signaling in the DMBA/TPA 
in response to necrotic cells (  15  ), and it 
may also have important tumor-intrinsic 
eff  ects. IL-1     was recently shown to be 
required for MCA-induced tumor for-
mation, suggesting that, in this system, 
MyD88 may function through the IL-
1R (  16  ). 
  Consistent with the importance of 
sterile infl  ammation in tumor promotion, 
the fi  ndings of Gebhart et al. (  7  ) in this 
issue implicate endogenous proteins re-
leased during cell necrosis in inciting 
carcinogenic infl  ammation. RAGE acti-
vation can occur through the recognition 
of at least three self-proteins released from 
cells during necrosis: the DNA-binding 
protein HMGB1 and the two calcium-
binding   “  cytokines  ”   S100a8 and S100a9. 
Intriguingly, RAGE-dependent recogni-
tion of HMGB1 has been shown to act 
in a costimulatory capacity for TLR-
mediated responses to DNA, potentially 
providing a link between RAGE and 
MyD88 (  17  ). 
  Taking off the breaks 
  Acute, self-limiting infl  ammation is gener-
ally insuffi   cient to promote tumor forma-
tion. Failure of normal antiinfl  ammatory 
    Figure 1.     Signals through innate immune receptors such as RAGE maintain chronic infl  am-
mation in the tumor microenvironment.   Chronic  infl  ammatory responses can be initiated by 
microbial or endogenous TLR ligands, or by RAGE ligands (s100a8, s100a9, and HMGB1) released from 
necrotic cells. These signals drive the expression of NF-    B  –  activating cytokines, such as TNF, IL-1   , 
and IL-6, which act as growth factors for the tumor. IL-17 produced by CD4 
+   T cells may also pro-
mote angiogenesis. At the same time, the tumor microenvironment disables potentially protective 
immune responses mediated by IFN-    – secreting  CD4 
+   and  CD8 
+   T  cells.   JEM VOL. 205, February 18, 2008  269
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engaged. Feed-forward signals such as 
those initiated by RAGE lead to uncon-
trolled, chronic immune activation. In 
this setting, any potentially protective 
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door to novel approaches to cancer treat-
ment and prevention. 
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